Anti-interleukin-6 receptor antibody prevents loss of bone structure and bone strength in collagen-induced arthritis mice
Authors:
- 10 April 2018
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 47 (5) , 384-391
Abstract
Objective: Rheumatoid arthritis (RA) is a disease that typically induces secondary osteoporosis, which increases the risk of bone fractures. Anti-interleukin-6 (IL-6) receptor antibody is used to treat RA; however, its effect on bone strength is not clear. Therefore, we investigated the influence of MR16-1, an anti-mouse IL-6 receptor antibody, on bone structure and femoral strength in a collagen-induced arthritis (CIA) mouse model. Method: DBA/1J mice were immunized by intradermal injection of bovine type II collagen. MR16-1 was administered intraperitoneally at the same time as immunization. Thirty-five days after the first immunization, bone structure and bone strength were measured by micro-computed tomography and the three-point bending test. Results: In the CIA group, most bone mineral density and bone structure parameters in the foot, femur, and lumbar spine were significantly lower than in the normal group. Moreover, the maximum load of the femoral shaft in the CIA group was significantly lower than in the normal group. MR16-1 treatment significantly prevented the CIA-induced deterioration of bone structure and loss of bone strength. Conclusion: These results suggest that CIA systemically induces a deterioration of bone structure and loss of bone strength, and that IL-6 signalling plays an important role in these processes.Keywords
This publication has 32 references indexed in Scilit:
- The effect of tocilizumab on bone mineral density, serum levels of Dickkopf-1 and bone remodeling markers in patients with rheumatoid arthritisJoint Bone Spine, 2015
- The effect of tocilizumab on bone mineral density in patients with methotrexate-resistant active rheumatoid arthritisRheumatology, 2014
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structuArthritis & Rheumatism, 2011
- Clinical assessment of the long‐term risk of fracture in patients with rheumatoid arthritisArthritis & Rheumatism, 2006
- Osteoporosis Prevention, Diagnosis, and TherapyJAMA, 2001
- Oral corticosteroids and fracture risk: relationship to daily and cumulative dosesRheumatology, 2000
- Use of Oral Corticosteroids and Risk of FracturesJournal of Bone and Mineral Research, 2000
- Association between Corticosteroid Use and Vertebral Fractures in Older Men with Chronic Obstructive Pulmonary DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Low dose long-term corticosteroid therapy in rheumatoid arthritis: An analysis of serious adverse eventsThe American Journal of Medicine, 1994
- Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients with Rheumatoid ArthritisAnnals of Internal Medicine, 1993